Supplementary Online Table 1. Articles Reviewed with Reason for Exclusion

|  |  |
| --- | --- |
| Article | Reason for Exclusion |
| 1. Altabas K, Bilić A, Jurcić D, et al. The efficacy of cisapride vs. placebo and diet in patients with chronic constipation. Collegium antropologicum 2003;27:197-204.
 | Different Endpoint used/not extractable |
| 1. Ojetti V, Ianiro G, Tortora A, et al. The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial. J Gastrointestin Liver Dis 2014;23:387-91.
 | Different Endpoint used/not extractable |
| 1. Barish CF, Drossman D, Johanson JF, et al. Efficacy and safety of lubiprostone in patients with chronic constipation. Digestive Diseases and Sciences 2010;55:1090-1097.
 | Different Endpoint used/not extractable |
| 1. Fukudo S, Hongo M, Kaneko H, et al. Lubiprostone Increases Spontaneous Bowel Movement Frequency and Quality of Life in Patients With Chronic Idiopathic Constipation. Clinical Gastroenterology and Hepatology 2015;13:294-U121
 | Different Endpoint used/not extractable |
| 1. Christie J, Shroff S, Shahnavaz N, et al. A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients. American Journal of Gastroenterology 2017;112:356-364.
 | Different Endpoint used/not extractable |
| 1. DiPalma JA, Cleveland MVB, McGowan J, et al. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. American Journal of Gastroenterology 2007;102:1436-1441.
 | Different Endpoint used/not extractable |
| 1. Emmanuel A, Cools M, Vandeplassche L, et al. Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: An integrated analysis. American Journal of Gastroenterology 2014;109:887-894.
 | Different Endpoint used/not extractable |
| 1. Coremans G. Prucalopride: the evidence for its use in the treatment of chronic constipation. Core Evidence 2008;3:45-54
 | Review Article |
| 1. Naumann J, Sadaghiani C, Alt F, et al. Effects of Sulfate-Rich Mineral Water on Functional Constipation: A Double-Blind, Randomized, Placebo-Controlled Study. Forsch Komplementmed 2016;23:356-363.
 | Different Endpoint used/not extractable |
| 1. Kienzle-Horn S, Vix JM, Schuijt C, et al. Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study. Alimentary Pharmacology & Therapeutics 2006;23:1479-1488.
 | Different Endpoint used/not extractable |
| 1. Muller-Lissner SA, Boehm G, Schulz-Merkel D. Treatment of chronic constipation with cisapride and placebo. Gut 1987;28:1033-1038.
 | Different Endpoint used/not extractable |
| 1. Taghavi SA, Shabani S, Mehramiri A, et al. Colchicine is effective for short-term treatment of slow transit constipation: A double-blind placebo-controlled clinical trial. International Journal of Colorectal Disease 2010;25:389-394.
 | Different Endpoint used/not extractable |
| 1. Verne GN, Davis RH, Robinson ME, et al. Treatment of chronic constipation with colchicine: randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol 2003;98:1112-6.
 | Different Endpoint used/not extractable |
| 1. Baek HI, Ha KC, Kim HM, et al. Randomized, double-blind, placebo-controlled trial of Ficus carica paste for the management of functional constipation. Asia Pac J Clin Nutr 2016;25:487-96.
 | Different Endpoint used/not extractable |
| 1. Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. American Journal of Gastroenterology 2009;104:125-132.
 | Study design: Study <4 weeks |
| 1. Johanson JF, Morton D, Geenen J, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. American Journal of Gastroenterology 2008;103:170-177.
 | Different Endpoint used/not extractable |
| 1. Sloots CEJ, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Alimentary Pharmacology & Therapeutics 2002;16:759-767.
 | Study design: Study <4 weeks |
| 1. Wulkow R, Vix JM, Schuijt C, et al. Randomised, placebo-controlled, double-blind study to investigate the efficacy and safety of the acute use of sodium picosulphate in patients with chronic constipation. International Journal of Clinical Practice 2007;61:944-950.
 | Study design: Study <4 weeks |
| 1. Degen L, Petrig C, Studer D, et al. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005;17:821-6.
 | Study design: healthy subjects |
| 1. Evans BW, Clark WK, Moore DJ, et al. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database of Systematic Reviews 2007:43.
 | Review |
| 1. Jia G, Meng MB, Huang ZW, et al. Treatment of functional constipation with the Yun-chang capsule: a double-blind, randomized, placebo-controlled, dose-escalation trial. J Gastroenterol Hepatol 2010;25:487-93.
 | Study design: Study <4 weeks |
| 1. Simren M, Bajor A, Gillberg PG, et al. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study. Aliment Pharmacol Ther 2011;34:41-50.
 | Study design: Study <4 weeks |
| 1. DiPalma JA, Cleveland MVB, McGowan J, et al. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. American Journal of Gastroenterology 2007;102:1436-1441.
 | Different Endpoint used/not extractable |
| 1. Chey WD, Lembo AJ, Rosenbaum DP. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial. Am J Gastroenterol 2017;112:763-774
 | IBS |
| 1. Brock C, Olesen SS, Olesen AE, et al. Opioid-Induced Bowel Dysfunction Pathophysiology and Management. Drugs 2012;72:1847-1865.
 | Review |
| 1. Yang Y, Fang J, Guo X, et al. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions. J Gastroenterol Hepatol 2018;33:980-989.
 | IBS |

*.*